Peptide Library
Semaglutide vs Tirzepatide vs Retatrutide
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
 Semaglutide |  Tirzepatide |  Retatrutide | |
|---|---|---|---|
| What it is | GLP-1 agonist, weight & glucose control | Dual GIP/GLP-1 agonist: weight & glucose control | Triple incretin agonist: metabolic health and weight loss |
| Type | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | Tri-agonist (GIP/GLP-1/Gcgr) |
| Structure | 31 aa, GLP-1 analog | 39 aa, lipidated peptide (Eli Lilly) | 39 aa, lipidated peptide (Eli Lilly) |
| Status | FDA approved | — | — |
| Route | SC, heti 1× / weekly | — | — |
| Storage | 2–8°C | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Source | Placeholder, image later | — | — |
| Molecular weight | — | ~4814 Da | ~4824 Da |
| Target area | — | T2DM, obesity | Weight loss, T2DM |
| Stability | — | ~30 days (reconstituted) | ~28 days (reconstituted) |
| Full entry | Open → | Open → | Open → |
What it is
SemaglutideGLP-1 agonist, weight & glucose control
TirzepatideDual GIP/GLP-1 agonist: weight & glucose control
RetatrutideTriple incretin agonist: metabolic health and weight loss
Type
SemaglutideGLP-1 receptor agonist
TirzepatideGIP/GLP-1 dual agonist
RetatrutideTri-agonist (GIP/GLP-1/Gcgr)
Structure
Semaglutide31 aa, GLP-1 analog
Tirzepatide39 aa, lipidated peptide (Eli Lilly)
Retatrutide39 aa, lipidated peptide (Eli Lilly)
Status
SemaglutideFDA approved
Tirzepatide—
Retatrutide—
Route
SemaglutideSC, heti 1× / weekly
Tirzepatide—
Retatrutide—
Storage
Semaglutide2–8°C
Tirzepatide2–8°C (reconstituted)
Retatrutide2–8°C (reconstituted)
Source
SemaglutidePlaceholder, image later
Tirzepatide—
Retatrutide—
Molecular weight
Semaglutide—
Tirzepatide~4814 Da
Retatrutide~4824 Da
Target area
Semaglutide—
TirzepatideT2DM, obesity
RetatrutideWeight loss, T2DM
Stability
Semaglutide—
Tirzepatide~30 days (reconstituted)
Retatrutide~28 days (reconstituted)